Health ❯Healthcare ❯Patient Care ❯Chronic Illness

Dementia

NICE Bars New Alzheimer’s Antibodies from NHS Over Cost and Capacity

Manufacturers plan to appeal a verdict that deems the medicines too costly for their modest benefits.

Australia Approves Donanemab as First Disease-Modifying Alzheimer’s Therapy

NHS Rejects Alzheimer’s Drug Donanemab Despite Promising Results

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs